| http://www.w3.org/ns/prov#value | - ic benefit might also be present because existing treatments are not satisfactory and alternative methods with an improved expected benefit risk balance are needed.The definitive PIP Guideline contains a substantively identical criterion.[29] The Ombudsman notes that a Summary of Product Characteristics is a document required before any medicinal product is authorized for marketing.
|
